20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Lakefront Biotherapeutics - American Depositary Shares (LKFT) operates in the NASDAQ industry and is headquartered in Mechelen, Belgium with about 196 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, LKFT reported €1.1B in revenue and €321M in net income.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Interactive charts & full statements → Open the LKFT valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €991M | €1.1B | €276M | €240M | €241M |
| Gross Profit | €940M | €1.1B | €241M | €240M | €241M |
| Gross Margin % | 94.9% | 97.3% | 87.4% | 100.0% | 100.0% |
| Operating Income (EBIT) | €610M | €501M | (€188M) | (€88M) | (€131M) |
| Operating Margin % | 61.6% | 45.1% | -68.3% | -36.8% | -54.3% |
| Net Income | €597M | €321M | €74M | €212M | (€218M) |
| Net Margin % | 60.2% | 28.8% | 26.9% | 88.3% | -90.4% |
| EBITDA | €542M | €359M | €43M | €51M | €4M |
| Earnings Per Share (EPS) | €9.05 | €4.87 | €1.12 | €3.21 | €-3.32 |
| Shares Outstanding (M) | 67M | 66M | 66M | 66M | 66M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | €12M | €6M | €901M | €71M | €65M | €75M |
| Gross Profit | (€23M) | €2M | €900M | €60M | €61M | €61M |
| Gross Margin % | -185.8% | 25.9% | 100.0% | 84.8% | 92.8% | 81.7% |
| Operating Income (EBIT) | (€43M) | (€64M) | €759M | (€42M) | (€57M) | (€159M) |
| Operating Margin % | -358.9% | -982.9% | 84.2% | -58.6% | -87.4% | -211.7% |
| Net Income | €2M | €14M | €782M | (€202M) | (€106M) | (€153M) |
| Net Margin % | 17.4% | 223.6% | 86.8% | -284.0% | -162.0% | -204.6% |
| EBITDA | (€35M) | €14M | €560M | €2M | (€101M) | — |
| Earnings Per Share (EPS) | €0.03 | €0.22 | €11.87 | €-3.07 | €-1.60 | €-2.33 |
| Shares Outstanding (M) | 67M | 66M | 66M | 66M | 66M | 66M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | (€227M) | (€257M) | (€320M) | (€406M) | (€501M) |
| Capital Expenditures (CapEx) | €5M | €14M | €82M | €19M | €37M |
| Free Cash Flow (FCF) | (€232M) | (€271M) | (€402M) | (€425M) | (€537M) |
| FCF Margin % | -23.4% | -24.4% | -145.9% | -177.4% | -222.8% |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | (€34M) | (€83M) | (€47M) | (€63M) | (€109M) | (€39M) |
| Capital Expenditures (CapEx) | €0M | €0M | €2M | €3M | €4M | €5M |
| Free Cash Flow (FCF) | (€34M) | (€83M) | (€49M) | (€65M) | (€113M) | (€44M) |
| FCF Margin % | -281.5% | -1278.7% | -5.5% | -92.0% | -173.0% | -58.5% |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | €3.4B | €3.4B | €4.1B | €4.4B | €4.7B |
| Cash & Cash Equivalents | €136M | €88M | €64M | €167M | €508M |
| Total Liabilities | €88M | €171M | €1.2B | €1.6B | €2.2B |
| Total Debt (Short + Long-Term) | €2M | €2M | €0M | €0M | €0M |
| Total Shareholders' Equity | €3.3B | €3.2B | €2.9B | €2.8B | €2.5B |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LKFT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms